# New Hampshire House Passes Scaled-Back Psilocybin Bill, Rejects Gun Rights Measure

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/psilocybin-policy-developments-new-hampshire-bill/
> **Published:** 2026-03-31T14:07:56-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:34:03-04:00
> **Clinical Summary:** Explore psilocybin policy developments as New Hampshire passes a scaled-back bill affecting clinical access and regulation of psychedelic therapies.

---

✦ New
CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely.
⚒ Cannabis News  |  CED Clinic
PolicyPsilocybinPsychedelicsMental HealthRegulatory

Why This Matters

Legislative developments in psilocybin policy create regulatory uncertainty that affects clinical planning and [patient access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/) to emerging psychedelic therapies. The patchwork of state-level policy changes requires clinicians to understand evolving legal frameworks when counseling patients about treatment options.

Clinical Summary
New Hampshire’s House passed a modified psilocybin bill while rejecting [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) patient gun rights protections, reflecting the complex state-by-state policy landscape for controlled substances in medicine. Psilocybin remains federally controlled despite growing research evidence for treatment-resistant depression and PTSD. The legislative action represents incremental policy movement rather than immediate clinical access changes.

Dr. Caplan’s Take

“Policy moves like this signal shifting acceptance of psychedelic medicine, but patients need to understand that legislative progress doesn’t equal clinical availability or safety oversight. We’re still years away from regulated therapeutic psilocybin in most jurisdictions.”

Clinical Perspective
🧠 Clinicians should monitor [state policy](https://cedclinic.com/will-the-coronavirus-force-states-to-legalize-marijuana/) developments while maintaining evidence-based counseling about currently available treatments. Patients inquiring about psilocybin therapy should be directed to FDA-approved [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) when appropriate, rather than unregulated sources that lack safety oversight.

💬 Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/)

Have thoughts on this? Share it:

[𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20New%20Hampshire%20House%20Passes%20Scaled-Back%20Psilocybin%20Bill%2C%20While%20Rejecting%20Measure%20...%20%40drcaplan&url=https%3A//www.marijuanamoment.net/new-hampshire-house-passes-scaled-back-psilocybin-bill-while-rejecting-measure-to-protect-medical-marijuana-patients-gun-rights/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.marijuanamoment.net/new-hampshire-house-passes-scaled-back-psilocybin-bill-while-rejecting-measure-to-protect-medical-marijuana-patients-gun-rights/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20New%20Hampshire%20House%20Passes%20Scaled-Back%20Psilocybin%20Bill%2C%20While%20Rejecting%20Measure%20...%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.marijuanamoment.net/new-hampshire-house-passes-scaled-back-psilocybin-bill-while-rejecting-measure-to-protect-medical-marijuana-patients-gun-rights/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/)

📰 Source: [https://www.marijuanamoment.net/new-hampshire-house-passes-scaled-back-psilocybin-bill-while-rejecting-measure-to-protect-medical-marijuana-patients-gun-rights/](https://www.marijuanamoment.net/new-hampshire-house-passes-scaled-back-psilocybin-bill-while-rejecting-measure-to-protect-medical-marijuana-patients-gun-rights/)

Table of Contents

- [FAQ](#FAQ)[What is the clinical relevance rating for this psilocybin development?](#What_is_the_clinical_relevance_rating_for_this_psilocybin_development)
- [What therapeutic area does this psilocybin news focus on?](#What_therapeutic_area_does_this_psilocybin_news_focus_on)
- [Is this a recent development in psilocybin policy or research?](#Is_this_a_recent_development_in_psilocybin_policy_or_research)
- [What type of psilocybin development does this article cover?](#What_type_of_psilocybin_development_does_this_article_cover)
- [Why should clinicians pay attention to this psilocybin news?](#Why_should_clinicians_pay_attention_to_this_psilocybin_news)
- [Related](#Related)

## FAQ

#### What is the clinical relevance rating for this psilocybin development?

This article has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This rating suggests emerging findings or policy developments that are worth monitoring closely by healthcare professionals.

#### What therapeutic area does this psilocybin news focus on?

Based on the tags, this development relates to mental health applications of psilocybin. The article appears to cover policy changes or clinical findings relevant to psychedelic-assisted therapy for mental health conditions.

#### Is this a recent development in psilocybin policy or research?

Yes, this is marked as “New” content from CED Clinic’s cannabis and psychedelics news coverage. The timing suggests this represents current or very recent developments in the psilocybin field.

#### What type of psilocybin development does this article cover?

The article focuses on policy-related developments concerning psilocybin and psychedelics. This could include regulatory changes, treatment approvals, or other policy shifts affecting clinical access or research.

#### Why should clinicians pay attention to this psilocybin news?

The “Notable Clinical Interest” rating indicates this development could impact clinical practice or [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-review/). Healthcare providers should monitor these emerging policy and research developments to stay current with evolving psychedelic medicine opportunities.

{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “New Hampshire House Passes Scaled-Back Psilocybin Bill, While Rejecting Measure To …”, “url”: “https://www.marijuanamoment.net/new-hampshire-house-passes-scaled-back-psilocybin-bill-while-rejecting-measure-to-protect-medical-marijuana-patients-gun-rights/”, “datePublished”: “2026-03-31T13:43:31Z”, “about”: “new hampshire house passes scaled back”}

 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance

 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Medical Consulting](https://cedclinic.com/book/)
 [Cannabis Care](https://cedclinic.com/book/)
 

 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

RELATED READING AT CED CLINIC

Continue exploring the evidence

[Joe Rogan praises Trump's executive order on psychedelics research](https://cedclinic.com/psychedelic-research-funding-impact-trump-executive-order/)

Learn about the recent executive order accelerating psychedelics research and its potential impact on clinical access.

[Read More](https://cedclinic.com/psychedelic-research-funding-impact-trump-executive-order/)

[Trump Signs Order To Accelerate Legal Access To Psychedelics For Patients](https://cedclinic.com/accelerate-psychedelic-assisted-therapies-mental-health-access/)

Explore how federal policy changes aim to improve [patient access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/) to psychedelic therapies.

[Explore Details](https://cedclinic.com/accelerate-psychedelic-assisted-therapies-mental-health-access/)

[Here's what psychedelics actually do to the brain](https://cedclinic.com/psychedelics-neuropharmacology-mental-health/)

Understand the neuroscience behind psychedelics and their therapeutic potential.

[Learn More](https://cedclinic.com/psychedelics-neuropharmacology-mental-health/)

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).